New Mexico Drug Laws: Penalties, Charges & Treatment Options

§ 30-31-23

Under NMSA § 30-31-23, it is unlawful for any person to intentionally possess a controlled substance unless obtained pursuant to a valid prescription or as otherwise authorized by the Controlled Substances Act (NMSA Chapter 30, Article 31). New Mexico does not distinguish between schedules for simple possession penalties — possession of any amount of a Schedule I through IV substance is a misdemeanor. This relatively uniform approach reflects the state's emphasis on treatment over incarceration for personal-use amounts.

§ 66-8-102

NMSA § 66-8-102 makes it unlawful for any person who is under the influence of intoxicating liquor to drive any vehicle in New Mexico. It is also unlawful for any person who is under the influence of any drug to a degree that renders them incapable of safely driving a vehicle to drive in the state. New Mexico uses the term DWI (Driving While Intoxicated) rather than DUI. The law distinguishes between standard DWI and Aggravated DWI (BAC of 0.16 or above, refusal to submit to testing, or causing bodily injury while DWI).

0.08% (0.04% for commercial drivers; 0.02% for under 21)

0.16% or higher

New Mexico is an implied consent state under § 66-8-107; refusal to submit to chemical testing results in automatic 1-year license revocation.

DWAI (Driving While Ability Impaired) applies to any drug — illegal, prescription, or over-the-counter — that impairs driving ability. No per se drug concentration limit; impairment assessed through observation, field sobriety tests, and blood/urine toxicology.

New Mexico was the first state in the nation to enact legislation to increase access to naloxone in 2001. The New Mexico Department of Health operates a comprehensive naloxone distribution program, and pharmacies may dispense naloxone (Narcan) without an individual prescription pursuant to a statewide standing order from the Department of Health. Community-based harm reduction programs throughout the state also distribute naloxone at no cost.

• Pharmacies may dispense naloxone without a patient-specific prescription under a statewide standing order from the NM Department of Health.
• The NM Department of Health distributes naloxone free of charge through harm reduction programs and public health offices.
• Liability protections exist for prescribers, dispensers, and individuals who administer naloxone in good faith.
• The Harm Reduction Act (NMSA § 24-2C-1 et seq.) authorizes harm reduction programs to distribute naloxone, syringes, and other supplies.
• HB 52 (2022) expanded the Harm Reduction Act to allow distribution of fentanyl test strips and other drug-checking supplies.

New Mexico Department of Health (NMDOH)

https://www.nmhealth.org/about/phd/idb/hrp/

Treatment Courts (Drug Courts)

New Mexico operates a statewide network of Treatment Courts (including Drug Courts) as alternatives to traditional criminal prosecution for individuals with substance use disorders. These courts provide intensive, court-supervised treatment programs designed to reduce recidivism, restore individuals to healthy and sober lives, and serve as cost-effective alternatives to incarceration. The Administrative Office of the Courts manages the Therapeutic Justice Support Program, which oversees all treatment court types.

• Adult Drug Courts
• Juvenile Drug Courts
• DWI Courts (including Hybrid DWI/Drug Courts)
• Family Dependency Treatment Courts
• Veterans Treatment Courts
• Behavioral Health Courts

Operating in multiple judicial districts statewide, including the Second Judicial District (Bernalillo County/Albuquerque), Third Judicial District (Dona Ana County/Las Cruces), and others.

Eligibility typically requires a diagnosis of substance use disorder and felony-level criminal charges. Violent offenses and certain serious felonies may disqualify participation. The court conducts a screening and assessment process before admission.

https://treatmentcourts.nmcourts.gov/

New Mexico generally does not impose state-level mandatory minimum sentences for most drug possession offenses, reflecting the state's treatment-oriented approach. However, mandatory minimums apply to certain DWI offenses and repeat drug distribution convictions. Federal mandatory minimums apply separately to cases prosecuted in federal court.

• DWI — 3rd offense — Mandatory Minimum: 30 days jail
• DWI — 4th offense — Mandatory Minimum: 6 months imprisonment (non-suspendable portion of 18-month sentence)
• DWI — 5th offense — Mandatory Minimum: 1 year imprisonment (non-suspendable portion of 2-year sentence)
• DWI — 6th offense — Mandatory Minimum: 18 months imprisonment (non-suspendable portion of 30-month sentence)
• DWI — 7th or subsequent offense — Mandatory Minimum: 2 years imprisonment (non-suspendable portion of 3-year sentence)
• Distribution to a minor — Mandatory Minimum: Varies; first degree felony classification ensures substantial imprisonment

Federal mandatory minimums apply to drug trafficking cases prosecuted in U.S. District Court for the District of New Mexico, including 5-year minimums for fentanyl (40g+) and 10-year minimums for larger quantities (400g+).

See drug_courts section — Treatment Courts provide judicially supervised treatment as an alternative to incarceration across multiple court types.

Under the Harm Reduction Act (NMSA § 24-2C-1 et seq.), the Department of Health authorizes community-based harm reduction programs to distribute syringes, naloxone, fentanyl test strips, and other supplies. These programs also provide referrals to substance abuse treatment services.

2021: Cannabis Regulation Act (HB 2): Legalized recreational marijuana for adults 21+, established the Cannabis Control Division, and provided for automatic expungement of prior marijuana convictions.

2022: HB 52: Expanded the Harm Reduction Act to authorize distribution of fentanyl test strips and other drug-checking supplies through harm reduction programs, and allowed distribution of sterile smoking supplies.

2022: Licensed retail cannabis sales launched April 1, 2022, with a 12% excise tax on top of regular gross receipts tax.

2023: Opioid settlement funds: General Appropriation Act allocated $21 million to state agencies for opioid remediation services; Opioid Settlement Restricted Fund and Opioid Crisis Recovery Fund created to distribute settlement revenues.

2024: Ongoing legislative efforts to strengthen fentanyl trafficking penalties, including bills to increase sentences for distribution of fentanyl resulting in death.

2025: Cannabis excise tax increased to 13% per the scheduled annual 1% increase under the Cannabis Regulation Act, on track to reach 18% by 2030.

2025: SB 410 and other fentanyl-related bills advanced in the 2025 legislative session, addressing enhanced penalties for trafficking and distribution of fentanyl and fentanyl analogues.